Cloning And Mutagenesis Market Size Worth $9.29 Billion By 2030 | CAGR: 18.7%

Cloning And Mutagenesis Market Size Worth $9.29 Billion By 2030 | CAGR: 18.7%

The global cloning and mutagenesis market size is expected to reach USD 9.29 billion by 2030, according to a new study by Polaris Market Research. The report “Cloning And Mutagenesis Market Share, Size, Trends, Industry Analysis Report, By Product (Cloning Kits, Mutagenesis Kits); By Technology; By End-use; By Region; Segment Forecast, 2022 - 2030” gives a detailed insight into current market dynamics and provides analysis on future market growth.


The global increase in the DNA and gene cloning services market is driven by the advancement of DNA sequencing technology, its growing application in clinical diagnostics and drug discovery, and an increase in R&D spending. Forensics, reproductive health, customized medicine, biomarkers, and diagnostics are just a few fields in which DNA sequencing is used. Recent research has shown that next-generation sequencing (NGS) technology can quickly and economically find and characterize clinically relevant genetic variations across various genes in a single test. Companies are also providing sequencing services. For instance, in December 2020, Eurofins Genomics introduced cost-effective and optimized SARS-CoV-2 NGS services, enabling the sequencing of the whole viral genome.


The purpose of gene therapy is to treat diseases by modifying genetic material, such as deactivating faulty genes or exchanging a disease-causing gene for a healthy copy. Various illnesses are being treated with gene therapy efficiently. Gene therapy can treat conditions like AIDS, diabetes, cancer, and heart disease.


The market is driven by a strong product portfolio, increased investment by major players, a high prevalence of target diseases, and interest in novel & innovative therapies. However, high product development costs and strict management standards are projected to constrain the global market. Increased R&D spending by public and private institutions is anticipated to open up new prospects in the worldwide cloning and mutagenesis market.


Have Questions? Request a sample or make an Inquiry before buying this report by clicking the link below:


The COVID-19 epidemic has benefited the global market because lockdown measures have been implemented in many nations, which has increased the use of PCR for the detection and analysis of particular gene sequences, which primarily utilizes oligonucleotides as a primer, functioning as a catalyst for industry expansion. Oligonucleotides are widely employed in the biopharmaceutical sector for dsDNA binding, aptamer creation, and allele-specific tests. Moreover, the market is anticipated to present attractive potential in the upcoming years due to the growing utilization of DNA computing, CRISPR gene editing, and mutagenesis investigations.


Cloning And Mutagenesis Market Report Highlights

  • In 2021, the TOPO PCR category dominated the market. TOPO PCR cloning is seeing increased use across a variety of end users, including pharmaceutical and biotech corporations and academic and research institutions.
  • The pharmaceutical and biopharmaceutical companies dominated the revenue in 2021. Pharmaceutical and biopharmaceutical companies are focusing on drug discovery and development due to the rise in disease frequency.
  • North America emerged as the largest regional share in 2021. This substantial percentage can be attributed to the increased demand for biotechnology techniques. Cloning and mutagenesis methods have also become more popular in the region as platforms based on genomic and proteomic data have grown.
  • The global players include Agilent Technologies, Inc., Thermo Fisher Scientific, Inc., New England Biolabs, Takara Bio Inc., Merck KGaA, Promega Corporation, Bio-Rad Laboratories, Inc., Danaher, Jena Bioscience GmbH, Assay Genie, TransGen Biotech Co., Ltd.


Polaris Market Research has segmented the cloning and mutagenesis market report based on product, technology, end-use, and region:


Cloning And Mutagenesis, Product Outlook (Revenue - USD Billion, 2018 - 2030)

  • Cloning Kits
  • Mutagenesis Kits

Cloning And Mutagenesis, Technology Outlook (Revenue - USD Billion, 2018 - 2030)

  • TOPO PCR Cloning
  • Site-directed Mutagenesis

Cloning And Mutagenesis, End-Use Outlook (Revenue - USD Billion, 2018 - 2030)

  • Biopharmaceuticals and pharmaceutical companies
  • CROs and CMOS

Cloning And Mutagenesis, Regional Outlook (Revenue - USD Billion, 2018 - 2030)

  • North America
    • U.S
    • Canada
  • Europe
    • Germany
    • UK
    • France
    • Italy
    • Spain
    • Russia
    • Netherlands
  • Asia Pacific
    • China
    • India
    • Japan
    • South Korea
    • Indonesia
    • Malaysia
  • Latin America
    • Argentina
    • Brazil
    • Mexico
  • Middle East & Africa
    • UAE
    • Saudi Arabia
    • Israel
    • South Africa